Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...